Cargando…

Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target

Clear cell ovarian cancer (CCOC) is an epithelial ovarian cancer histotype with unique pathologic, biologic and clinical features. Despite its worse prognosis than serous ovarian cancer (SOC), the genomic landscape of CCOC is less well defined. Integrated genomic analysis of CCOC allows the identifi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsang, Tsun Yee, Wei, Wei, Itamochi, Hiroaki, Tambouret, Rosemary, Birrer, Michael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Priority Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722499/ https://www.ncbi.nlm.nih.gov/pubmed/29228547 http://dx.doi.org/10.18632/oncotarget.19946

Ejemplares similares

PRKCI promotes immune suppression in ovarian cancer
por: Sarkar, Sharmistha, et al.
Publicado: (2017)

In Vivo Conditions to Identify Prkci Phosphorylation Targets Using the Analog-Sensitive Kinase Method in Zebrafish
por: Cibrián Uhalte, Elena, et al.
Publicado: (2012)

Role and mechanism of circ-PRKCI in hepatocellular carcinoma
por: Qi, Su-Xia, et al.
Publicado: (2019)

Prkci Regulates Autophagy and Pancreatic Tumorigenesis in Mice
por: Inman, Kristin S., et al.
Publicado: (2022)

Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer
por: Hampras, Shalaka S., et al.
Publicado: (2016)

Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas
por: Shoji, Tadahiro, et al.
Publicado: (2021)

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors
por: Baldelli, Elisa, et al.
Publicado: (2015)

Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma
por: Molejon, Maria Inés, et al.
Publicado: (2015)

Addiction to protein kinase Cɩ due to PRKCI gene amplification can be exploited for an aptamer-based targeted therapy in ovarian cancer
por: Rehmani, Hina, et al.
Publicado: (2020)

A unifying gene signature for adenoid cystic cancer identifies parallel MYB-dependent and MYB-independent therapeutic targets
por: Gao, Ruli, et al.
Publicado: (2014)

Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity
por: Ketola, Kirsi, et al.
Publicado: (2021)

Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma
por: Duffy, David J., et al.
Publicado: (2015)

Comparison of SARS-CoV-2 RT-PCR on a high-throughput molecular diagnostic platform and the cobas SARS-CoV-2 test for the diagnostic of COVID-19 on various clinical samples
por: Opota, Onya, et al.
Publicado: (2020)

A targeted genetic association study of epithelial ovarian cancer susceptibility
por: Earp, Madalene, et al.
Publicado: (2016)

Impact of deleterious missense PRKCI variants on structural and functional dynamics of protein
por: Shah, Hania, et al.
Publicado: (2022)

TCF21 hypermethylation in genetically quiescent clear cell sarcoma of the kidney
por: Gooskens, Saskia L., et al.
Publicado: (2015)

Targeting ovarian cancer and endothelium with an allosteric PTP4A3 phosphatase inhibitor
por: McQueeney, Kelley E., et al.
Publicado: (2017)

Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer
por: Oran, Amanda R., et al.
Publicado: (2016)

Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers
por: Stany, Michael P., et al.
Publicado: (2011)

Induction of DISE in ovarian cancer cells in vivo
por: Murmann, Andrea E., et al.
Publicado: (2017)

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer
por: Iskit, Sedef, et al.
Publicado: (2016)

PRKCI Mediates Radiosensitivity via the Hedgehog/GLI1 Pathway in Cervical Cancer
por: Wu, Zhuna, et al.
Publicado: (2022)

The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas
por: D'Andrea, Aleco, et al.
Publicado: (2016)

Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci
por: Glubb, Dylan M., et al.
Publicado: (2017)

Cripto-1 as a novel therapeutic target for triple negative breast cancer
por: Castro, Nadia P., et al.
Publicado: (2014)

Surgical management of non-invasive uterine clear cell carcinoma
por: Sugiyama, Toru, et al.
Publicado: (2017)

Genome-wide Regional Heritability Mapping Identifies a Locus Within the TOX2 Gene Associated With Major Depressive Disorder
por: Zeng, Yanni, et al.
Publicado: (2017)

Exome sequencing analysis of murine medulloblastoma models identifies WDR11 as a potential tumor suppressor in Group 3 tumors
por: Wei, Lei, et al.
Publicado: (2017)

Targeting multidrug-resistant ovarian cancer through estrogen receptor α dependent ATP depletion caused by hyperactivation of the unfolded protein response
por: Zheng, Xiaobin, et al.
Publicado: (2016)

Circular RNA PRKCI promotes glioma cell progression by inhibiting microRNA-545
por: Zhang, Xuebang, et al.
Publicado: (2019)

Investigation of UTR Variants by Computational Approaches Reveal Their Functional Significance in PRKCI Gene Regulation
por: Shah, Hania, et al.
Publicado: (2023)

Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing
por: Chen, Gregory M., et al.
Publicado: (2023)

The PAX8 cistrome in epithelial ovarian cancer
por: Adler, Emily K., et al.
Publicado: (2017)

Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy
por: Tang, Jack Pengfei, et al.
Publicado: (2022)

Antioxidants and Therapeutic Targets in Ovarian Clear Cell Carcinoma
por: Amano, Tsukuru, et al.
Publicado: (2021)

Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition
por: Lamb, Rebecca, et al.
Publicado: (2014)

Soluble IL6R represents a miR-34a target: potential implications for the recently identified IL-6R/STAT3/miR-34a feed-back loop
por: Li, Huihui, et al.
Publicado: (2015)

A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas
por: Beauchamp, Roberta L., et al.
Publicado: (2015)

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
por: Valent, Peter, et al.
Publicado: (2017)

Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma
por: Itamochi, Hiroaki, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_d11sj681n6l44t7ir8gk0mq51a